Aimmune Therapeutics (AIMT) Takeaways From Allergist KOL Call - RBC

RBC Capital analyst, Kennen MacKay, reiterated his Outperform rating on shares of Aimmune Therapeutics (NASDAQ: AIMT) conducting a KOL call to discuss AIMT's AR101 ph3 PALISADE data presented at the AAAAI 2018 conference. Overall, the KOL came away from AAAAI conference impressed with AR101's efficacy and safety which was unexpectedly lower vs. historical OIT trials.

The analyst stated "we see AR101 as well-positioned to disrupt and build the peanut allergy desensitization market as the regulatory process and commercial prep come into focus".

No change to the price target of $62.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $34.75 yesterday.

You May Also Be Interested In

• RBC Capital Downgrades Super Retail Group Ltd. (SUL:AU) to Sector Perform
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Aveanna selling stockholders launch 15M share secondary offering